Biocryst Pharmaceuticals (BCRX) Total Debt Growth (5y) (2016 - 2026)
Biocryst Pharmaceuticals (BCRX) Total Debt Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.21% |
| Mar 31, 2026 | 28.76% |
| Dec 31, 2025 | -20.70% |
| Sep 30, 2025 | 38.19% |
| Mar 31, 2025 | 47.24% |
| Dec 31, 2024 | 107.57% |
| Sep 30, 2024 | 47.31% |
| Jun 30, 2024 | 47.05% |
| Mar 31, 2024 | 46.47% |
| Dec 31, 2023 | 61.28% |
| Sep 30, 2023 | 58.37% |
| Jun 30, 2023 | 71.09% |
| Mar 31, 2023 | 60.83% |
| Dec 31, 2022 | 58.42% |
| Sep 30, 2022 | 57.49% |
| Jun 30, 2022 | 44.43% |
| Mar 31, 2022 | 43.70% |
| Dec 31, 2021 | 67.26% |
| Sep 30, 2021 | 41.84% |
| Sep 30, 2020 | 8.94% |